Board and Management Team
Board
Dr Martin Blake
Chairman
MBBS, FRANZCR, FAANMS, MBA, FAICD
Dr Blake is a Radiologist and Nuclear Physician and brings a wealth of technical and industry experience to Resonance Health. He has been a partner of Perth Radiological Clinic since 1997 and is currently the Chairman of the company. Dr Blake additionally held the position of Head of Department of Nuclear Medicine at Royal Perth Hospital for a numbers of years. He has published more than a dozen peer review research papers and has been contributing author to the Royal Australian and New Zealand College of Radiologists (RANZCR) Imaging Guidelines. Dr Blake has additionally held positions as Secretary and Treasurer of the WA Branch of the RANZCR. Dr Blake has an MBA from Melbourne University, is a Graduate of the Australian Institute of Company Directors and holds directorships on a number of company boards.
Mr Simon Panton
Non Executive Director
Mr Panton has been a major shareholder of Resonance Health since 2008 and joined the board in 2009, as he is strong believer in liver health technologies. Mr Panton started and ran his own successful small business for over 15 years and brings skills in business and marketing. He has experience in the property industry, financial markets, and the acquisition and disposal of investments. He currently manages assets and projects associated within family holdings and was a previous Non-Executive Director of 4DS Ltd.
Dr Travis Baroni
Non Executive Director
Dr Travis Baroni has broad experience across industrial research, commercialisation of technology, asset valuations, and investment banking services. He has managed innovation development and technology strategy in a large company setting as well as being an active investor in early stage investments. He has worked in investment banking, providing advisory services to equity capital market transactions, corporate research, and valuations to clients.
Mr Mitchell Wells
Non Executive Director
Mr Mitchell Wells is an experienced senior executive and a qualified lawyer with commerical and legal experience in Australia, the United States of America and the United Kingdom. He has served as a director and worked as a senior executive of listed-public and private companies including ASX and Nasdaq listed companies. He currently serves as Chair of two not-for-profit organisations.
Alison Laws
Chief Executive Officer
Bsc, Grad Dip Env Sci
Alison joined Resonance Health in 2016, having significant previous experience in building a software company. Prior to this, she lectured in Business Statistics, and has worked in a range of commerical analysis roles for small, medium, and large businesses. Alison has previously worked in the role of Global Account Manager and Chief Business Development Officer for Resonance and is now Chief Executive Officer.
Mr Agha Shahzad
Chief Financial Officer and Company Secretary
BSc (IT) Hons, M. Com (Professional Accounting)
Mr Agha Shahzad has over ten years experience in managing the financial obligations of ASX listed corporations across a diverse range of industries. He joined Resonance Health in 2009 and has in-depth knowledge of all financial and operational aspects of Resonance. Agha has also been responsible for the handling of EMDG rebates and R&D Tax Incentive claims for the last several years.
In his personal time, Agha is an active member of his local community in Harrisdale, WA. He is involved with several not-for-profit initiatives to help the disadvantaged, including spending his weekends feeding the homeless and volunteering his help at large community events. He is married with two beautiful children and loves to spend time with his family.
Prof Tim St Pierre
Chief Scientific Officer
BSc (Hons) PhD
Professor St Pierre is a widely published physicist in the field of iron in medicine and biology. He has built a reputation for his pre-eminent understanding of the fundamental properties of the iron deposits that occur in iron overload diseases. Professor St Pierre led the team which developed the non-invasive liver iron measurement technology, FerriScan®, which has been used in over 35,000 patient measurements in hospitals around the world. He has also developed technologies for measurement of liver fat and detection of parasites in human blood, faeces, and urine. He has published over 180 peer reviewed papers in the fields of iron and magnetism in biology, biotechnology, and medicine.
In 2010 he won a Clunies Ross Award from the Australian Academy of Technological Sciences and Engineering for his work on non-invasive measurement of tissue iron deposits. During 2014 he was an IEEE Magnetics Society Distinguished Lecturer on magnetic materials in medicine. In 2015 he won the Ernst and Young Western Region Entrepreneur of the Year Award (Technology category) and in 2016 the Panos Englezos Prize from the Thalassaemia International Federation for his contribution to the improvement of health for patients with thalassaemia.
Celine Royet
Quality Assurance and Regulatory Affairs Manager
Pharm. D
Celine joined Resonance Health in 2015 as the Quality Assurance & Regulatory Affairs Manager. Celine has over 12 years of experience in the pharmaceutical and medical devices industry in Europe (France & UK) and Australia. She is a Doctor of Pharmacy (France) and holds an additional Masters Degree specialised in QA/QC for cell therapy and gene therapy products.
Dr Wenjie Pang
Technical & Research Manager
PhD
Wenjie hails from China, where he enjoyed a successful career researching magnetism in different forms. He came to the University of Western Australia as a visiting research fellow in the Department of Physics. Following an International Scholarship to study for his PhD and some time at the University of Colorado in the US, Wenjie became one of the first employees of Resonance Health in 2005.
Wenjie’ s roles in the company have been pivotal and varied. He has been heavily involved in R&D across FerriScan, HepaFat-Scan and liver fibrosis measurement and his work has also resulted in a significant shortening of the MRI scan time required for FerriScan. Most recently Wenjie has worked closely with the marketing team to explore the market in China and provide clinical education.
Since moving to Western Australia, Wenjie and his wife greeted the arrival of their second child, and he enjoys playing bridge and various sports in his spare time.
Dr Sherif Boulos
Clinical Research Manager
PhD
Sherif is tasked with identifying and co-ordinating clinical studies in which Resonance Health’s products can add value. With a focus on HepaFat-Scan and our developing liver fibrosis technology, his work has already led to a number of new and important studies in the NAFLD/NASH and diabetes fields.
Prior to joining Resonance Health, he established a research laboratory investigating brain diseases while teaching undergraduates and supervising post-graduate students. Well before this time, he worked as a sales engineer, product specialist, and technical sales executive with a number of medical and laboratory supply companies. Combined, his working life has spanned both the academic and commercial worlds.
Married with two teenaged children, he enjoys Perth’s abundant coastal lifestyle while occasionally finding time to play guitar.
Assoc. Prof. Michael House
Scientific Research Officer
PhD
Research Associate Professor Michael House is a biophysicist in the School of Physics at The University of Western Australia and a Scientific Research Officer at Resonance Health. He has extensive experience in quantitative magnetic resonance imaging (MRI) techniques to non-invasively assess human diseases including Alzheimer’s disease, liver fibrosis and steatosis, and iron overload in the brain, heart, kidneys, liver and bone marrow and has published over 50 peer-reviewed articles and abstracts. His expertise in quantitative MRI techniques provides an important contribution to the R&D team in Resonance Health's commitment to enhance existing products and broaden its portfolio. He is also one of the inventors listed on the international patent application for the non-invasive measurement of liver fat (HepaFat-Scan).